Welcome!

News Feed Item

UK Injectables Market Outlook to 2017

NEW YORK, Feb. 17, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

UK Injectables Market Outlook to 2017
http://www.reportlinker.com/p01622848/UK-Injectables-Market-Outlook-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Injectables occupy a considerable prominence in UK irrespective of diminishing growth in the pharmaceutical market for 2-3 years. The advancements in technology up-gradation and investments have provided immense growth opportunities for injectables to emerge in the UK's pharmaceutical industry in recent years. According to RNCOS' research report, "UK Injectables Market Outlook to 2017", the market is anticipated to grow at a CAGR of approximately 4.5% during 2012-2017. The increasing need of injectables for diseases like diabetes, infectious diseases and arthritis is primarily driving this market.

The said report is a study of the UK injectable market in terms of major therapeutic areas. It covers the historical sales trend of injectables for categories such as Diabetes, Vaccines, Sex Hormones & Antagonist in Malign Disease, Anticoagulants & Protamine, Hypothalamic & Pituitary Hormones, Rheumatic Diseases & Gout, etc. Not only this, the report also provides the sales trend of the top 10 injectable drugs in the UK market along with a rational analysis.

Certain pharmaceutical firms in UK's injectable market have established their foothold given the diverse and innovative product offerings. Several small pharma majors too have been aggressively competing with big pharmaceutical players in order to establish themselves in the market. The report highlights a detailed comparison of the market shares of different players in the injectables market.

The study provides an insight about the competitive landscape, which includes business profiling and a strength-weakness analysis of top pharmaceutical players in the UK injectable business. There's also a coverage of the detailed analysis of their top injectable drugs in terms of revenue.

A lot of investment is being done in research and development of injectables in order to improve their medical outcomes. Here it is worth mentioning that even the country's government has significantly contributed towards the development of innovative medicines.

Moreover, the Government has shifted its focus towards cost effective drug treatments by fixing up the drug prices as per their clinical value. In addition, there are a set of regulations that support the injectable drug business in the country. In this context, various regulatory processes such as drug licensing, marketing/ promotion, pricing etc. have been comprehensively covered in the report. In a nutshell, the report covers every aspect of UK injectables which will help the industry players to take strategic decisions.

1. Analyst View

2. Research Methodology

3. UK Injectables Market Outlook to 2017
3.1 Current and Future Market Analysis
3.1.1 By Top 10 Injectables
3.1.2 By Top 10 Therapeutics
3.1.3 By Major Players

4. Drivers and Challenges
4.1 Drivers
4.2 Challenges

5. Regulatory Environment

6. Competitive Landscape
6.1 Novo Nordisk
6.1.1 Business Overview
6.1.2 Key Injectable Sales
6.1.3 Strengths and Weaknesses
6.1.4 Recent Developments
6.2 Sanofi
6.2.1 Business Overview
6.2.2 Key Injectable Sales
6.2.3 Strengths and Weaknesses
6.2.4 Recent Developments
6.3 Eli Lily & Co.
6.3.1 Business Overview
6.3.2 Key Injectable Sales
6.3.3 Strengths and Weaknesses
6.4 Pfizer
6.4.1 Business Overview
6.4.2 Key Injectable Sales
6.4.3 Strengths and Weaknesses
6.4.4 Recent Developments
6.5 Abbott Laboratories
6.5.1 Business Overview
6.5.2 Key Injectable Sales
6.5.3 Strengths and Weaknesses
6.5.4 Recent Developments
6.6 Takeda Pharmaceutical Company Ltd
6.6.1 Business Overview
6.6.2 Key Injectable Sales
6.6.3 Strengths and Weaknesses
6.6.4 Recent Developments

List of Figures:

Figure 3-1: Injectables Market (Million £), 2012-2017
Figure 3-2: Injectables Market by Player (%), 2010
Figure 3-3: Injectables Market by Player (%), 2012
Figure 6-1: Novo Nordisk - Break up of Revenue by Business Segment (%), 2012
Figure 6-2: Novo Nordisk - Diabetes Care Revenue by Segment (%), 2012
Figure 6-3: Novo Nordisk UK - Break up of Revenue by Segment (%), 2012
Figure 6-4: Sanofi - Break up of Revenue by Business Segment (%), 2012
Figure 6-5: Eli Lily & Co. - Break up of Revenue by Business Segment (%), 2012
Figure 6-6: Eli Lily & Co. - Human Pharmaceutical Division Revenue by Segment (%), 2012
Figure 6-7: Pfizer - Break up of Revenue by Business Segment (%), 2012

List of Tables:

Table 3-1: Top 10 Injectable Sales (Million £), 2010-2012
Table 3-2: Injectable Sales by Top 10 Therapeutics (Million £), 2010-2012
Table 6-1: Novo Nordisk UK - Key Injectable Sales (Million £), 2010-2012
Table 6-2: Novo Nordisk UK - Strengths and Weaknesses
Table 6-3: Sanofi UK - Key Injectable Sales (Million £), 2010-2012
Table 6-4: Sanofi UK - Strengths and Weaknesses
Table 6-5: Eli Lily & Co. UK - Key Injectable Sales (Million £), 2010-2012
Table 6-6: Eli Lily & Co. UK - Strengths and Weaknesses
Table 6-7: Pfizer UK - Key Injectable Sales (Million £), 2010-2012
Table 6-8: Pfizer UK - Strengths and Weaknesses
Table 6-9: Abbott Laboratories UK - Key Injectable Sales (Million £), 2010-2012
Table 6-10: Abbott Laboratories UK - Strengths and Weaknesses
Table 6-11: Takeda Pharmaceuticals UK - Key Injectable Sales (Million £), 2010-2012
Table 6-12: Takeda Pharmaceuticals UK - Strengths and Weaknesses

To order this report: UK Injectables Market Outlook to 2017
http://www.reportlinker.com/p01622848/UK-Injectables-Market-Outlook-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The best-practices for building IoT applications with Go Code that attendees can use to build their own IoT applications. In his session at @ThingsExpo, Indraneel Mitra, Senior Solutions Architect & Technology Evangelist at Cognizant, provided valuable information and resources for both novice and experienced developers on how to get started with IoT and Golang in a day. He also provided information on how to use Intel Arduino Kit, Go Robotics API and AWS IoT stack to build an application tha...
IoT generates lots of temporal data. But how do you unlock its value? You need to discover patterns that are repeatable in vast quantities of data, understand their meaning, and implement scalable monitoring across multiple data streams in order to monetize the discoveries and insights. Motif discovery and deep learning platforms are emerging to visualize sensor data, to search for patterns and to build application that can monitor real time streams efficiently. In his session at @ThingsExpo, ...
Manufacturers are embracing the Industrial Internet the same way consumers are leveraging Fitbits – to improve overall health and wellness. Both can provide consistent measurement, visibility, and suggest performance improvements customized to help reach goals. Fitbit users can view real-time data and make adjustments to increase their activity. In his session at @ThingsExpo, Mark Bernardo Professional Services Leader, Americas, at GE Digital, discussed how leveraging the Industrial Internet a...
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
Extracting business value from Internet of Things (IoT) data doesn’t happen overnight. There are several requirements that must be satisfied, including IoT device enablement, data analysis, real-time detection of complex events and automated orchestration of actions. Unfortunately, too many companies fall short in achieving their business goals by implementing incomplete solutions or not focusing on tangible use cases. In his general session at @ThingsExpo, Dave McCarthy, Director of Products...
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, discussed the importance of WebRTC and how it enables companies to focus...
Amazon has gradually rolled out parts of its IoT offerings in the last year, but these are just the tip of the iceberg. In addition to optimizing their back-end AWS offerings, Amazon is laying the ground work to be a major force in IoT – especially in the connected home and office. Amazon is extending its reach by building on its dominant Cloud IoT platform, its Dash Button strategy, recently announced Replenishment Services, the Echo/Alexa voice recognition control platform, the 6-7 strategic...
Aspose.Total for .NET is the most complete package of all file format APIs for .NET as offered by Aspose. It empowers developers to create, edit, render, print and convert between a wide range of popular document formats within any .NET, C#, ASP.NET and VB.NET applications. Aspose compiles all .NET APIs on a daily basis to ensure that it contains the most up to date versions of each of Aspose .NET APIs. If a new .NET API or a new version of existing APIs is released during the subscription peri...
Verizon Communications Inc. (NYSE, Nasdaq: VZ) and Yahoo! Inc. (Nasdaq: YHOO) have entered into a definitive agreement under which Verizon will acquire Yahoo's operating business for approximately $4.83 billion in cash, subject to customary closing adjustments. Yahoo informs, connects and entertains a global audience of more than 1 billion monthly active users** -- including 600 million monthly active mobile users*** through its search, communications and digital content products. Yahoo also co...
Ixia (Nasdaq: XXIA) has announced that NoviFlow Inc.has deployed IxNetwork® to validate the company’s designs and accelerate the delivery of its proven, reliable products. Based in Montréal, NoviFlow Inc. supports network carriers, hyperscale data center operators, and enterprises seeking greater network control and flexibility, network scalability, and the capacity to handle extremely large numbers of flows, while maintaining maximum network performance. To meet these requirements, NoviFlow in...
As companies gain momentum, the need to maintain high quality products can outstrip their development team’s bandwidth for QA. Building out a large QA team (whether in-house or outsourced) can slow down development and significantly increases costs. This eBook takes QA profiles from 5 companies who successfully scaled up production without building a large QA team and includes: What to consider when choosing CI/CD tools How culture and communication can make or break implementation
"There's a growing demand from users for things to be faster. When you think about all the transactions or interactions users will have with your product and everything that is between those transactions and interactions - what drives us at Catchpoint Systems is the idea to measure that and to analyze it," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York Ci...
Redis is not only the fastest database, but it is the most popular among the new wave of databases running in containers. Redis speeds up just about every data interaction between your users or operational systems. In his session at 19th Cloud Expo, Dave Nielsen, Developer Advocate, Redis Labs, will share the functions and data structures used to solve everyday use cases that are driving Redis' popularity.
UpGuard has become a member of the Center for Internet Security (CIS), and will continue to help businesses expand visibility into their cyber risk by providing hardening benchmarks to all customers. By incorporating these benchmarks, UpGuard's CSTAR solution builds on its lead in providing the most complete assessment of both internal and external cyber risk. CIS benchmarks are a widely accepted set of hardening guidelines that have been publicly available for years. Numerous solutions exist t...
"We're bringing out a new application monitoring system to the DevOps space. It manages large enterprise applications that are distributed throughout a node in many enterprises and we manage them as one collective," explained Kevin Barnes, President of eCube Systems, in this SYS-CON.tv interview at DevOps at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.